Worth reading
34Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Items stated in the management plan
Annual updateNet SalesNot disclosed → ¥15,000 millions (medium to long term, approximately ¥15 billion)
Only the target level is shown because the current level for comparison was not provided.What happened to the previous planNot disclosed → Revenue: 23.1% above budget; operating profit: 0.4% above budget（Revenue +23.1%; operating profit +0.4%）
Key initiatives
01Accelerating group growth through a strategic global structure
02Establishing a foundation for sustainable growth spanning the United States and China
03Management through delegated authority and experienced leadership
04Next-generation drug discovery engine
05Clinical, manufacturing, and sales operations in China
06High-margin vertically integrated model
07F351 will generate demand and create a new market
08Aiming to discover new drugs using the proprietary uSMITETM targeted protein degradation technology platform
Plan assumptionsGyre's approximately $300 million all-stock acquisition of Cullgen is targeted for completion during the second quarter of 2026., Completion requires clearance under U.S. antitrust law, Gyre shareholder approval for the conversion of preferred shares, and satisfaction of customary M&A closing conditions.
Segment targetSegment MedTech Business / Sales Target Approximately ¥15 billion (¥15,000 million) / Operating profit target Not disclosed / Timing Medium- to Long-Term Outlook
Size of the Target MarketMarket Acute pain market / Dimensions Approximately ¥300 billion ($1.8 billion) in 2030 / Source Evaluate Pharma, query on acute pain market 5-13-2025, Market Acute and chronic pain market / Dimensions Approximately ¥16.4 trillion ($106 billion) in 2030 / Source World Health Organization, Market Chinese liver fibrosis market / Dimensions ¥51–67 billion (¥107.5–140 billion) / Source Market data and other sources. Sources cited for the top 3 drugs include Zhongkang CMH, investor presentation materials from Fu Rui Co., securities company research reports, and YaoNet.
Risks identified by the company
Gyre's acquisition of Cullgen requires clearance under U.S. antitrust law, Gyre shareholder approval for the conversion of preferred shares, and satisfaction of customary M&A closing conditions.
The development details and schedule may change depending on progress.
Market forecasts may differ materially from actual results due to various risks and uncertainties.
The projected number of patients for F351 may change if the underlying assumptions change.
| Item | Details |
|---|---|
| Plan name | Business Plan and Growth Potential |
| Progress against the plan | Annual update |
| Sales Target | Not disclosed → ¥15,000 millions (medium to long term, approximately ¥15 billion) |
| Segment target | Segment MedTech Business / Sales Target Approximately ¥15 billion (¥15,000 million) / Operating profit target Not disclosed / Timing Medium- to Long-Term Outlook |
| Plan assumptions | Gyre's approximately $300 million all-stock acquisition of Cullgen is targeted for completion during the second quarter of 2026., Completion requires clearance under U.S. antitrust law, Gyre shareholder approval for the conversion of preferred shares, and satisfaction of customary M&A closing conditions. |
| Key initiatives | Accelerating group growth through a strategic global structure, Establishing a foundation for sustainable growth spanning the United States and China, Management through delegated authority and experienced leadership, Next-generation drug discovery engine, Clinical, manufacturing, and sales operations in China, High-margin vertically integrated model, F351 will generate demand and create a new market, Aiming to discover new drugs using the proprietary uSMITETM targeted protein degradation technology platform |
| Results under the previous plan | Not disclosed → Revenue: 23.1% above budget; operating profit: 0.4% above budget（Revenue +23.1%; operating profit +0.4%） |
| Size of the Target Market | Market Acute pain market / Dimensions Approximately ¥300 billion ($1.8 billion) in 2030 / Source Evaluate Pharma, query on acute pain market 5-13-2025, Market Acute and chronic pain market / Dimensions Approximately ¥16.4 trillion ($106 billion) in 2030 / Source World Health Organization, Market Chinese liver fibrosis market / Dimensions ¥51–67 billion (¥107.5–140 billion) / Source Market data and other sources. Sources cited for the top 3 drugs include Zhongkang CMH, investor presentation materials from Fu Rui Co., securities company research reports, and YaoNet. |
| Risks identified | Gyre's acquisition of Cullgen requires clearance under U.S. antitrust law, Gyre shareholder approval for the conversion of preferred shares, and satisfaction of customary M&A closing conditions., The development details and schedule may change depending on progress., Market forecasts may differ materially from actual results due to various risks and uncertainties., The projected number of patients for F351 may change if the underlying assumptions change. |
Items this document does not state (16)
Plan periodOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorNon-financial targetsReason for revision or withdrawalDate of board resolutionPublication date
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.